[go: up one dir, main page]

BRPI0816690A2 - derivados 1-amino-alquilciclohexano para tratamento e a prevenção da perda da audição - Google Patents

derivados 1-amino-alquilciclohexano para tratamento e a prevenção da perda da audição

Info

Publication number
BRPI0816690A2
BRPI0816690A2 BRPI0816690A BRPI0816690A BRPI0816690A2 BR PI0816690 A2 BRPI0816690 A2 BR PI0816690A2 BR PI0816690 A BRPI0816690 A BR PI0816690A BR PI0816690 A BRPI0816690 A BR PI0816690A BR PI0816690 A2 BRPI0816690 A2 BR PI0816690A2
Authority
BR
Brazil
Prior art keywords
prevention
amino
treatment
hearing loss
alkylcyclohexane derivatives
Prior art date
Application number
BRPI0816690A
Other languages
English (en)
Inventor
Hagen Krueger
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of BRPI0816690A2 publication Critical patent/BRPI0816690A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0816690A 2007-09-12 2008-09-10 derivados 1-amino-alquilciclohexano para tratamento e a prevenção da perda da audição BRPI0816690A2 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US99339607P 2007-09-12 2007-09-12
EP07253630 2007-09-12
US6702608P 2008-02-25 2008-02-25
US6693108P 2008-02-25 2008-02-25
US6708308P 2008-02-25 2008-02-25
EP08004778 2008-03-14
EP08004777 2008-03-14
EP08004776 2008-03-14
PCT/EP2008/007419 WO2009033650A1 (en) 2007-09-12 2008-09-10 1-amino-alkylcyclohexane derivatives for the treatment and prevention of hearing loss

Publications (1)

Publication Number Publication Date
BRPI0816690A2 true BRPI0816690A2 (pt) 2016-11-01

Family

ID=40451596

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0816712A BRPI0816712A2 (pt) 2007-09-12 2008-09-10 terapia de intervalo para o tratamento de tinnitus
BRPI0816690A BRPI0816690A2 (pt) 2007-09-12 2008-09-10 derivados 1-amino-alquilciclohexano para tratamento e a prevenção da perda da audição

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0816712A BRPI0816712A2 (pt) 2007-09-12 2008-09-10 terapia de intervalo para o tratamento de tinnitus

Country Status (21)

Country Link
US (6) US9498450B2 (pt)
EP (6) EP2200600B1 (pt)
JP (6) JP5563461B2 (pt)
KR (4) KR20100052556A (pt)
CN (4) CN101801365A (pt)
AR (3) AR070025A1 (pt)
AT (1) ATE532507T1 (pt)
AU (4) AU2008298015B2 (pt)
BR (2) BRPI0816712A2 (pt)
CA (4) CA2699207A1 (pt)
DK (1) DK2200600T3 (pt)
ES (5) ES2596262T3 (pt)
HR (1) HRP20120046T1 (pt)
MX (4) MX2010002733A (pt)
PL (1) PL2200600T3 (pt)
PT (1) PT2200600E (pt)
RU (1) RU2011137131A (pt)
SI (1) SI2200600T1 (pt)
TW (3) TW200922544A (pt)
WO (4) WO2009033652A1 (pt)
ZA (4) ZA201001264B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200922544A (en) * 2007-09-12 2009-06-01 Merz Pharma Gmbh & Amp Co Kgaa Interval therapy for the treatment of tinnitus
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
EP2585049A1 (en) 2010-06-24 2013-05-01 Merz Pharma GmbH & Co. KGaA Neramexane multiple unit dosage form
JP6084931B2 (ja) * 2011-01-20 2017-02-22 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン
AU2014225534A1 (en) * 2013-03-06 2015-09-24 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
EA201692163A1 (ru) * 2014-04-28 2017-03-31 Керин Фармасьютикал Ко., Лтд. Лекарственное средство для лечения пациентов с тиннитусом
EA201692164A1 (ru) * 2014-04-28 2017-03-31 Керин Фармасьютикал Ко., Лтд. Лекарственное средство для лечения пациентов с тиннитусом
CA2999467C (en) * 2014-10-23 2023-10-10 Arena Pharmaceuticals, Inc. Method of treating conditions related to the pgi2 receptor
HUE056138T2 (hu) * 2015-05-18 2022-01-28 Sensorion Azasetron a halláskárosodás kezelésében való felhasználásra
KR101893604B1 (ko) 2015-08-27 2018-08-30 경희대학교 산학협력단 칸디다 유틸리스 추출물을 포함하는 난청의 예방 또는 치료용 조성물
CN105924362B (zh) * 2016-02-05 2018-08-17 上海龙翔生物医药开发有限公司 芳香环丙基胺类化合物、其药学上可接受的盐、其制备方法及其用途
WO2018160882A1 (en) 2017-03-01 2018-09-07 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
KR102268893B1 (ko) 2020-01-16 2021-06-24 경북대학교 산학협력단 림노트릭스 속 knua002 균주를 포함하는 난청의 예방 또는 치료용 조성물
CN111477199B (zh) * 2020-04-02 2021-11-30 北京瑞迪欧文化传播有限责任公司 一种嵌入式音乐控制系统
EP4297708A4 (en) * 2021-09-09 2024-08-28 Samsung Electronics Co., Ltd. AUDIO CONTENT DELIVERY MANAGEMENT

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4849222A (en) 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
DE69431404T2 (de) 1993-10-22 2003-04-30 Genentech Inc., San Francisco Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
DE19528388A1 (de) * 1995-08-02 1997-02-06 Hans Peter Prof Dr Med Zenner Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
WO1998010757A2 (en) * 1996-09-11 1998-03-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity
JP3963488B2 (ja) * 1997-06-30 2007-08-22 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツンク ウント コンパニー コマンディゲゼルシャフト アウフ アクチェン 1−アミノ−アルキルシクロヘキサンnmda受容体拮抗薬
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
HUP0300600A2 (hu) * 2000-04-26 2003-08-28 Warner-Lambert Co. Ciklohexil-amin-származékok mint altípus-szelektív NMDA receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények
DE10048969A1 (de) * 2000-08-23 2002-03-14 Mueller Schwefe Gerhard Verwendung von Flupirtin zur Tinnitusbehandlung
US20030236288A1 (en) * 2002-02-28 2003-12-25 Karl Schoenafinger Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
JP2004021734A (ja) 2002-06-18 2004-01-22 Nokia Corp キーパッドおよびキーパッドシステム
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
JP2006502158A (ja) * 2002-09-06 2006-01-19 デュレクト コーポレーション グルタメート媒介神経伝達のモジュレーターの内耳への送達
DE10252665A1 (de) 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
US20050014743A1 (en) * 2003-05-27 2005-01-20 Forest Laboratories, Inc. Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
ES2483126T3 (es) * 2004-06-17 2014-08-05 Merz Pharma Gmbh & Co. Kgaa Formulaciones de formas de dosificación de neramexano
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
EP1861161A4 (en) * 2005-01-24 2012-05-16 Neurosystec Corp APPARATUS AND METHOD FOR DISPENSING THERAPEUTIC AND / OR OTHER AGENTS IN THE INTERNAL EAR AND OTHER FABRICS
US20060205789A1 (en) * 2005-03-04 2006-09-14 Neurosystec Corporation Gacyclidine formulations
TWI265036B (en) * 2005-04-29 2006-11-01 Guo-Ming Huang Safety injector and method of operating the same
EP1898848B1 (en) * 2005-05-18 2010-11-24 GT Urological, LLC Drug elution for implantable incontinence devices
CN1896729A (zh) 2005-07-15 2007-01-17 复旦大学附属中山医院 纳米药物自组装双稳态量子线阵列及其制备方法
US20070141148A1 (en) 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
TW200819458A (en) * 2006-06-23 2008-05-01 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
TW200922544A (en) * 2007-09-12 2009-06-01 Merz Pharma Gmbh & Amp Co Kgaa Interval therapy for the treatment of tinnitus
TW201010691A (en) * 2008-06-12 2010-03-16 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
TW201006463A (en) * 2008-06-26 2010-02-16 Merz Pharma Gmbh & Co Kgaa Pharmaceutical compositions comprising aminocyclohexane derivatives
AU2009291244A1 (en) * 2008-09-10 2010-03-18 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of cognitive impairment in tinnitus
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
JP6084931B2 (ja) * 2011-01-20 2017-02-22 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン

Also Published As

Publication number Publication date
EP2200599A1 (en) 2010-06-30
JP5613053B2 (ja) 2014-10-22
HRP20120046T1 (hr) 2012-02-29
CA2699209A1 (en) 2009-03-19
AR070025A1 (es) 2010-03-10
ES2562709T3 (es) 2016-03-07
ES2596262T3 (es) 2017-01-05
US8877814B2 (en) 2014-11-04
SI2200600T1 (sl) 2012-03-30
JP5784189B2 (ja) 2015-09-24
JP2010539117A (ja) 2010-12-16
AU2008298015A1 (en) 2009-03-19
ES2377253T3 (es) 2012-03-23
AU2008298018B2 (en) 2012-01-19
US9498450B2 (en) 2016-11-22
EP2200599B1 (en) 2016-08-31
CA2699207A1 (en) 2009-03-19
ZA201001261B (en) 2011-08-31
EP2200600A1 (en) 2010-06-30
WO2009033650A1 (en) 2009-03-19
EP2548552A2 (en) 2013-01-23
AU2008298017B2 (en) 2012-03-01
AU2008298016A1 (en) 2009-03-19
ZA201001262B (en) 2011-07-27
TW200918042A (en) 2009-05-01
JP5563460B2 (ja) 2014-07-30
CN101801365A (zh) 2010-08-11
MX2010002734A (es) 2010-04-01
CN101801366A (zh) 2010-08-11
JP2010539115A (ja) 2010-12-16
MX2010002735A (es) 2010-04-01
US20150018425A1 (en) 2015-01-15
AU2008298016B2 (en) 2012-02-02
JP2010539118A (ja) 2010-12-16
KR20100052557A (ko) 2010-05-19
EP2386299B1 (en) 2016-07-13
DK2200600T3 (da) 2012-01-23
EP2548552B1 (en) 2015-11-18
US9468610B2 (en) 2016-10-18
AR071728A1 (es) 2010-07-14
KR20100052556A (ko) 2010-05-19
CN101795679A (zh) 2010-08-04
ES2604945T3 (es) 2017-03-10
EP2200600B1 (en) 2011-11-09
EP2386299A3 (en) 2012-05-02
TW200927087A (en) 2009-07-01
AU2008298017A1 (en) 2009-03-19
AU2008298018A1 (en) 2009-03-19
CA2699210A1 (en) 2009-03-19
JP5784188B2 (ja) 2015-09-24
JP2014221766A (ja) 2014-11-27
KR20100052559A (ko) 2010-05-19
EP2203163B1 (en) 2014-08-27
ATE532507T1 (de) 2011-11-15
BRPI0816712A2 (pt) 2016-11-08
CN101835469A (zh) 2010-09-15
MX2010002733A (es) 2010-04-09
JP5612473B2 (ja) 2014-10-22
CA2699213A1 (en) 2009-03-19
TW200922544A (en) 2009-06-01
JP2014221767A (ja) 2014-11-27
PT2200600E (pt) 2012-02-17
EP2386299A2 (en) 2011-11-16
WO2009033652A1 (en) 2009-03-19
US20100298440A1 (en) 2010-11-25
JP5563461B2 (ja) 2014-07-30
US20110077304A1 (en) 2011-03-31
US20100298441A1 (en) 2010-11-25
EP2200598A1 (en) 2010-06-30
JP2010539116A (ja) 2010-12-16
RU2011137131A (ru) 2013-03-20
US20110086916A1 (en) 2011-04-14
AU2008298018C1 (en) 2012-08-16
EP2548552A3 (en) 2013-10-16
ZA201001263B (en) 2011-07-27
ES2510565T3 (es) 2014-10-21
EP2203163A1 (en) 2010-07-07
MX2010002736A (es) 2010-04-01
ZA201001264B (en) 2011-07-27
PL2200600T3 (pl) 2012-04-30
WO2009033651A1 (en) 2009-03-19
KR20100052558A (ko) 2010-05-19
AU2008298015B2 (en) 2012-03-22
AR070026A1 (es) 2010-03-10
US20170027885A1 (en) 2017-02-02
WO2009033649A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
BRPI0816690A2 (pt) derivados 1-amino-alquilciclohexano para tratamento e a prevenção da perda da audição
NO2022027I1 (no) Combination of daunorubicin and cytarabine
DK3067066T3 (da) Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
BRPI0811142A2 (pt) Prevenção e tratamento de condições oculares associadas a complementos
BRPI0717389A2 (pt) Dispositivos e métodos para avanço de stent
BRPI0817082A2 (pt) Implantes lacrimais e métodos relacionados
BRPI0820399A2 (pt) Folha adesiva e método para fabricação da mesma.
BRPI0920206A2 (pt) dispositivos e métodos para manipulação de um eixo de cateter
DOP2010000044A (es) Derivado de oxopirazina y herbicida
BRPI0908379A2 (pt) sistemas e métodos para obter dentaduras customizadas
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BR112012003372A2 (pt) vitamina d3 e análogos da mesma para o tratamento de alopecia.
BRPI0815387A2 (pt) composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição
PT2349132T (pt) Aparelho para tratamento da drge
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
DE602007010795D1 (de) Blattsauger und -häcksler
DK2175851T3 (da) Biofilmbehandling
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
BRPI0817964A2 (pt) Implante cirúrgico
BRPI0813100A2 (pt) Preparação sólida farmacêutica e método de produção da mesma
BRPI0811870A2 (pt) Tratamento e prevenção de influenza
BRPI0924001A2 (pt) composição para desinfecção fotodinâmica e método de aplicação da mesma.
PL3067066T3 (pl) Zapobieganie i leczenie choroby synukleinopatycznej i amyloidogennej

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]